Primary prevention of atrial fibrillation with beta-blockers in patients with end-stage renal disease undergoing dialysis

Ting Tse Lin, Jiun Yang Chiang, Min Tsun Liao, Chia Ti Tsai, Juey Jen Hwang, Fu Tien Chiang, Jiunn Lee Lin, Lian Yu Lin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Current evidence suggests that beta-blocker lower the risk of development of atrial fibrillation (AF) and in-hospital stroke after cardiac surgery. This study was to assess whether beta-blockers could decrease incidence of new-onset AF in patients with end stage renal disease (ESRD). We identified patients from a nation-wide database called Registry for Catastrophic Illness, which encompassed almost 100% of the patients receiving dialysis therapy in Taiwan from 1995 to 2008. Propensity score matching and Cox € s proportional hazards regression model were used to estimate hazard ratios (HRs) for new-onset AF. Among 100066 patients, 41.7% received beta-blockers. After a median follow-up of 1500 days, the incidence of new-onset AF significantly decreased in patients treated with beta-blockers (HR = 0.483, 95% confidence interval = 0.437-0.534). The prevention of new-onset AF was significantly better in patients taking longer duration of beta-blockers therapy (P for time trend <0.001). The AF prevention effect remains robust in subgroup analyses. In conclusion, beta-blockers seem effective in the primary prevention of AF in ESRD patients. Hence, beta-blockers may be the target about upstream treatment of AF.

Original languageEnglish
Article number17731
JournalScientific Reports
Volume5
DOIs
Publication statusPublished - Dec 8 2015
Externally publishedYes

Fingerprint

Primary Prevention
Atrial Fibrillation
Chronic Kidney Failure
Dialysis
Catastrophic Illness
Propensity Score
Incidence
Taiwan
Proportional Hazards Models
Thoracic Surgery
Registries
Therapeutics
Stroke
Databases
Confidence Intervals

ASJC Scopus subject areas

  • General

Cite this

Lin, T. T., Chiang, J. Y., Liao, M. T., Tsai, C. T., Hwang, J. J., Chiang, F. T., ... Lin, L. Y. (2015). Primary prevention of atrial fibrillation with beta-blockers in patients with end-stage renal disease undergoing dialysis. Scientific Reports, 5, [17731]. https://doi.org/10.1038/srep17731

Primary prevention of atrial fibrillation with beta-blockers in patients with end-stage renal disease undergoing dialysis. / Lin, Ting Tse; Chiang, Jiun Yang; Liao, Min Tsun; Tsai, Chia Ti; Hwang, Juey Jen; Chiang, Fu Tien; Lin, Jiunn Lee; Lin, Lian Yu.

In: Scientific Reports, Vol. 5, 17731, 08.12.2015.

Research output: Contribution to journalArticle

Lin, Ting Tse ; Chiang, Jiun Yang ; Liao, Min Tsun ; Tsai, Chia Ti ; Hwang, Juey Jen ; Chiang, Fu Tien ; Lin, Jiunn Lee ; Lin, Lian Yu. / Primary prevention of atrial fibrillation with beta-blockers in patients with end-stage renal disease undergoing dialysis. In: Scientific Reports. 2015 ; Vol. 5.
@article{7b662fb5cac6484b8bdb62c1738b9340,
title = "Primary prevention of atrial fibrillation with beta-blockers in patients with end-stage renal disease undergoing dialysis",
abstract = "Current evidence suggests that beta-blocker lower the risk of development of atrial fibrillation (AF) and in-hospital stroke after cardiac surgery. This study was to assess whether beta-blockers could decrease incidence of new-onset AF in patients with end stage renal disease (ESRD). We identified patients from a nation-wide database called Registry for Catastrophic Illness, which encompassed almost 100{\%} of the patients receiving dialysis therapy in Taiwan from 1995 to 2008. Propensity score matching and Cox € s proportional hazards regression model were used to estimate hazard ratios (HRs) for new-onset AF. Among 100066 patients, 41.7{\%} received beta-blockers. After a median follow-up of 1500 days, the incidence of new-onset AF significantly decreased in patients treated with beta-blockers (HR = 0.483, 95{\%} confidence interval = 0.437-0.534). The prevention of new-onset AF was significantly better in patients taking longer duration of beta-blockers therapy (P for time trend <0.001). The AF prevention effect remains robust in subgroup analyses. In conclusion, beta-blockers seem effective in the primary prevention of AF in ESRD patients. Hence, beta-blockers may be the target about upstream treatment of AF.",
author = "Lin, {Ting Tse} and Chiang, {Jiun Yang} and Liao, {Min Tsun} and Tsai, {Chia Ti} and Hwang, {Juey Jen} and Chiang, {Fu Tien} and Lin, {Jiunn Lee} and Lin, {Lian Yu}",
year = "2015",
month = "12",
day = "8",
doi = "10.1038/srep17731",
language = "English",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Primary prevention of atrial fibrillation with beta-blockers in patients with end-stage renal disease undergoing dialysis

AU - Lin, Ting Tse

AU - Chiang, Jiun Yang

AU - Liao, Min Tsun

AU - Tsai, Chia Ti

AU - Hwang, Juey Jen

AU - Chiang, Fu Tien

AU - Lin, Jiunn Lee

AU - Lin, Lian Yu

PY - 2015/12/8

Y1 - 2015/12/8

N2 - Current evidence suggests that beta-blocker lower the risk of development of atrial fibrillation (AF) and in-hospital stroke after cardiac surgery. This study was to assess whether beta-blockers could decrease incidence of new-onset AF in patients with end stage renal disease (ESRD). We identified patients from a nation-wide database called Registry for Catastrophic Illness, which encompassed almost 100% of the patients receiving dialysis therapy in Taiwan from 1995 to 2008. Propensity score matching and Cox € s proportional hazards regression model were used to estimate hazard ratios (HRs) for new-onset AF. Among 100066 patients, 41.7% received beta-blockers. After a median follow-up of 1500 days, the incidence of new-onset AF significantly decreased in patients treated with beta-blockers (HR = 0.483, 95% confidence interval = 0.437-0.534). The prevention of new-onset AF was significantly better in patients taking longer duration of beta-blockers therapy (P for time trend <0.001). The AF prevention effect remains robust in subgroup analyses. In conclusion, beta-blockers seem effective in the primary prevention of AF in ESRD patients. Hence, beta-blockers may be the target about upstream treatment of AF.

AB - Current evidence suggests that beta-blocker lower the risk of development of atrial fibrillation (AF) and in-hospital stroke after cardiac surgery. This study was to assess whether beta-blockers could decrease incidence of new-onset AF in patients with end stage renal disease (ESRD). We identified patients from a nation-wide database called Registry for Catastrophic Illness, which encompassed almost 100% of the patients receiving dialysis therapy in Taiwan from 1995 to 2008. Propensity score matching and Cox € s proportional hazards regression model were used to estimate hazard ratios (HRs) for new-onset AF. Among 100066 patients, 41.7% received beta-blockers. After a median follow-up of 1500 days, the incidence of new-onset AF significantly decreased in patients treated with beta-blockers (HR = 0.483, 95% confidence interval = 0.437-0.534). The prevention of new-onset AF was significantly better in patients taking longer duration of beta-blockers therapy (P for time trend <0.001). The AF prevention effect remains robust in subgroup analyses. In conclusion, beta-blockers seem effective in the primary prevention of AF in ESRD patients. Hence, beta-blockers may be the target about upstream treatment of AF.

UR - http://www.scopus.com/inward/record.url?scp=84949595541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949595541&partnerID=8YFLogxK

U2 - 10.1038/srep17731

DO - 10.1038/srep17731

M3 - Article

VL - 5

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 17731

ER -